A detailed history of American Century Companies Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, American Century Companies Inc holds 181,250 shares of NBIX stock, worth $24.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
181,250
Previous 198,536 8.71%
Holding current value
$24.5 Million
Previous $27.3 Million 23.65%
% of portfolio
0.01%
Previous 0.02%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$114.58 - $153.15 $1.98 Million - $2.65 Million
-17,286 Reduced 8.71%
181,250 $20.9 Million
Q2 2024

Aug 07, 2024

SELL
$130.86 - $143.19 $3.73 Million - $4.08 Million
-28,483 Reduced 12.55%
198,536 $27.3 Million
Q1 2024

May 14, 2024

SELL
$130.4 - $143.74 $72.4 Million - $79.8 Million
-555,025 Reduced 70.97%
227,019 $31.3 Million
Q4 2023

Feb 13, 2024

BUY
$106.07 - $132.76 $83 Million - $104 Million
782,044 New
782,044 $103 Million
Q3 2023

Nov 13, 2023

SELL
$94.02 - $117.1 $8.51 Million - $10.6 Million
-90,523 Reduced 8.2%
1,013,744 $114 Million
Q2 2023

Aug 14, 2023

BUY
$89.53 - $104.87 $21.7 Million - $25.4 Million
242,362 Added 28.12%
1,104,267 $104 Million
Q1 2023

May 11, 2023

BUY
$94.11 - $123.02 $5.31 Million - $6.94 Million
56,405 Added 7.0%
861,905 $87.2 Million
Q4 2022

Feb 13, 2023

SELL
$106.72 - $127.06 $25.4 Million - $30.2 Million
-238,010 Reduced 22.81%
805,500 $96.2 Million
Q3 2022

Nov 14, 2022

SELL
$92.03 - $107.81 $6.38 Million - $7.47 Million
-69,322 Reduced 6.23%
1,043,510 $111 Million
Q2 2022

Aug 12, 2022

BUY
$75.79 - $100.07 $24 Million - $31.7 Million
316,984 Added 39.83%
1,112,832 $108 Million
Q1 2022

May 11, 2022

BUY
$72.45 - $94.81 $48.6 Million - $63.6 Million
670,415 Added 534.48%
795,848 $74.6 Million
Q4 2021

Feb 07, 2022

BUY
$79.65 - $106.22 $487,059 - $649,535
6,115 Added 5.12%
125,433 $10.7 Million
Q3 2021

Nov 10, 2021

SELL
$86.18 - $99.03 $962,716 - $1.11 Million
-11,171 Reduced 8.56%
119,318 $11.4 Million
Q2 2021

Aug 05, 2021

SELL
$89.43 - $102.27 $1.36 Million - $1.56 Million
-15,220 Reduced 10.45%
130,489 $12.7 Million
Q1 2021

May 14, 2021

SELL
$87.57 - $119.4 $26,971 - $36,775
-308 Reduced 0.21%
145,709 $14.2 Million
Q4 2020

Feb 12, 2021

SELL
$86.91 - $108.33 $4.92 Million - $6.13 Million
-56,578 Reduced 27.93%
146,017 $14 Million
Q3 2020

Nov 13, 2020

SELL
$96.16 - $135.15 $1.36 Million - $1.9 Million
-14,094 Reduced 6.5%
202,595 $19.5 Million
Q2 2020

Aug 13, 2020

BUY
$85.09 - $130.36 $4.95 Million - $7.58 Million
58,175 Added 36.7%
216,689 $26.4 Million
Q1 2020

May 14, 2020

SELL
$75.11 - $113.76 $5.6 Million - $8.48 Million
-74,509 Reduced 31.97%
158,514 $13.7 Million
Q4 2019

Feb 12, 2020

BUY
$86.8 - $118.57 $594,927 - $812,678
6,854 Added 3.03%
233,023 $25 Million
Q3 2019

Nov 13, 2019

BUY
$83.82 - $101.5 $28,163 - $34,104
336 Added 0.15%
226,169 $20.4 Million
Q2 2019

Aug 14, 2019

BUY
$72.24 - $91.27 $2.9 Million - $3.67 Million
40,185 Added 21.65%
225,833 $19.1 Million
Q1 2019

May 14, 2019

BUY
$69.31 - $91.53 $2.6 Million - $3.43 Million
37,507 Added 25.32%
185,648 $0
Q4 2018

Feb 13, 2019

BUY
$68.32 - $124.36 $10.1 Million - $18.4 Million
148,141 New
148,141 $10.6 Million
Q3 2018

Nov 02, 2018

SELL
$98.88 - $125.85 $56.1 Million - $71.3 Million
-566,895 Closed
0 $0
Q2 2018

Aug 08, 2018

BUY
$75.3 - $105.99 $5.25 Million - $7.39 Million
69,701 Added 14.02%
566,895 $55.7 Million
Q1 2018

May 03, 2018

BUY
$75.88 - $92.43 $496,710 - $605,046
6,546 Added 1.33%
497,194 $41.2 Million
Q4 2017

Feb 02, 2018

BUY
$58.53 - $77.59 $26.6 Million - $35.3 Million
454,500 Added 1257.33%
490,648 $38.1 Million
Q3 2017

Nov 01, 2017

BUY
$47.97 - $61.28 $1.73 Million - $2.22 Million
36,148
36,148 $2.22 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track American Century Companies Inc Portfolio

Follow American Century Companies Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Century Companies Inc, based on Form 13F filings with the SEC.

News

Stay updated on American Century Companies Inc with notifications on news.